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ABSTRACT
Aims: We investigated whether a lifestyle intervention could influence expression and DNAmethylation
of diabetes-related genes in patients with impaired glucose regulation (IGR), the results were compared
to bariatric surgery, considering it an intensive change. Methods: Twenty participants with IGR had
adipose tissue biopsy and blood collected pre- and post-lifestyle (6 months) intervention; 12 obese
patients had subcutaneous fat taken before and after bariatric surgery. RNA/DNAwas extracted from all
samples and underwent qPCR. DNA was bisulphite converted and 12 CpG sites of Caveolin-1 (CAV1)
promoter were pyrosequenced. Results: lifestyle intervention resulted in opposite direction changes in
fat tissue and blood for CAV1 expression and DNA methylation and these changes were correlated
between tissues, while no significative differences were found in CAV1 expression after bariatric surgery.
Conclusions: Our findings suggest a role for CAV1 inmodulating adipocyte function as a consequence of
lifestyle changes, as exercises and diet. These results may provide insights into new therapeutic targets
for diabetes prevention.
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1. Introduction
Type 2 diabetes mellitus (T2DM) in parallel with obe-
sity is responsible for a major reduction in life expec-
tancy and quality of life, increasing health-care costs
[1]. Prediabetes or impaired glucose regulation (IGR) is
a condition that precedes T2DM and can be identified
by mildly elevated glycated haemoglobin A1 c (HbA1 c)
[2,3]. The mechanisms which underlie the evolution
from IGR to T2DM are not currently understood.
In order to prevent patients with IGR becoming
diabetic, hospitals around the world implement pro-
grammes to reduce the risk of IGR progression [2].
Without any lifestyle or medical intervention, in parti-
cular weight loss and physical activity, more than 50%
of people who have IGR will develop T2DM, accom-
panied by an increased risk of cardiovascular disease
and cardiovascular death over a period of 10 y [4,5].
In Salford, UK we have a lifestyle change pro-
gramme called Care Call (http://www.srft.nhs.uk/
EasysiteWeb/getresource.axd?AssetID=119162&type=
full&servicetype=Inline) [6]. This is a non-face-to-face
telephone-based modular intervention programme,
which has been proven to benefit people with impaired
glucose regulation [7].
Both genetic and environmental factors may contri-
bute to the progression from IGR to T2DM, as may a
variety of other mechanisms that may mediate the
effect of drugs or other environmental influences on
clinical outcomes. One well-established process, that
might be particularly likely to interact with other
genetic factors, is that of epigenetics. Epigenetic
mechanisms can be defined as changes of a phenotype
such as the gene expression of a specific cell type that
are not caused by changes in the nucleotide sequence of
the genetic code itself [8]. Two such mechanisms are
DNA methylation and histone modifications; both
affect gene expression by changing the profiles of pro-
teins which bind to specific DNA regions, such as
transcription factors into promoter gene sequences
[9]. As these DNA methylation marks can be dynami-
cally regulated and programmed by environmental
cues, such as stress and diet, these epigenetic marks
may represent an interface between the genome and
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environment that could program risk for the develop-
ment of T2DM and obesity.
From genome-wide studies [10–14], we selected a
panel of candidate genes known to be involved in
glucose regulation and insulin resistance. Among
them, Caveolin-1 (CAV1) has been pointed out as one
of the genes upregulated in fat tissue of rats in response
to a high-fat diet [15] and shown to be involved in
insulin resistance [16]. CAV1 is considered an essential
element of adipocyte caveolae and has been shown to
be involved in the compartmentalization and integra-
tion of several signal transduction pathways in these
cavities [17].
We herein set out to investigate how a lifestyle
change programme may influence the genetic and epi-
genetic determinants linked with weight loss after a
lifestyle intervention programme and we compared
the lifestyle change with an invasive and intensive
change, i.e. bariatric surgery. In light of this, the aim
of this study was to evaluate the alterations in the
expression of a panel of genes, including CAV1, impli-
cated in the modulation of weight change and insulin
resistance. Additionally, we evaluated for those genes
for which we found altered expression with the inter-
vention, if there are associated changes in the DNA
methylation.
2. Material and methods
2.1. Sample collection
Patients with IGR (10 females and 10 males) living in
Salford were recruited from November 2014 to
November 2018 and underwent anthropometric mea-
surements including waist measurement and waist–hip
ratio before the start of the 6-month intervention, and
after its completion.
The study recruited individuals with IGR (cases)
through Care Call as well as healthy, age, sex and
BMI matched individuals (as controls) through
Citizen Scientist Website at Salford Royal NHS
Foundation Trust. For the present study, we are show-
ing only the results regarding the cases in two different
points: before and after an intervention, characterizing
as a prospective interventional study. The IGR indivi-
duals have been referred to the Salford Care Call inter-
vention by their GP, following administration of a
standard Oral Glucose Tolerance Test (OGTT) or
with an abnormal fasting glucose (>6 mmol/L) along
with raised glycosylated haemoglobin (Hba1 C of >42
and <48 mmol/mol). Care Call is an established tele-
phone-based service in Salford, aimed at improving the
glucose control of individuals with IGR by providing
guidance on lifestyle, healthy diet and regular exercise.
The CareCall and Eatwell guide are provided as a
supplementary material (S1).
Inclusion/exclusion criteria: Inclusion Criteria
(cases): (i) Patients with IGR (as defined in paragraph
2); (ii) Age 18–80 y. Exclusion criteria (cases): (i)Age
<18 y or >80 y; (ii) Unable or unwilling to provide
informed consent; (iii) Individuals on long-term
(>3 months) steroid therapy; (iv) Pregnancy; (v)
Cushing’s syndrome or active acromegaly.
All individuals participated in the Care Call
Programme. This is a modular intervention programme
which utilizes motivational support techniques, such as
lifestyle education, one-to-one and peer discussion and
encouragement of progress with goals and signposting/
referral to relevant services, also offering tailoring of
content to individual needs.
Salford Royal’s Diabetes Care Call is a telephone-
based service available to help people with diabetes and
has been further developed to also support people diag-
nosed with IGR presenting a high risk to develop
T2DM.
The Care Call programme is structured by offering
to the patients eight appointments by telephone with
personal and dietary advices; information about diet,
lifestyle and activity including tips that can help the
patients to reduce the risk to develop T2DM.
Additionally, an ‘Eatwell guide’ is offered to help the
patients to understand which types of food they should
aim to eat each day and what portion size should be. In
addition, the health advisors incentive the patients to be
more active, when patients are suitable the advisors can
refer them to any Fit City Centre located in Salford and
offer a free 8 weeks pass.
We also collected fat tissue and blood at two time
points, before and 6 months after the lifestyle interven-
tion. The complete description of samples collecting
was described before by our group [7].
This study was submitted to the Ethics committee of
Research and Development Department of Salford
Royal NHS Foundation Trust and the permission was
granted in accordance with the Research Governance
Framework (2005), Medicines for Human Uses
(Clinical Trials) Regulations (2004) and Salford Royal
NHS Foundation Trust local policies (proc number 14/
NW/1196).
We also recruited 12 obese patients (n = 5 with
T2DM and n = 7 without T2DM) waiting for bariatric
surgery at Salford Royal Hospital (Salford, UK). The
smoker’s patients were required to stop smoking from
at least 2 weeks before to the surgery date. All partici-
pants attended The Wellcome Trust Clinical Research
Facility (Manchester, UK) where they had taken
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subcutaneous fat tissue samples at baseline and
6 months after the surgery (n = 10 were submitted to
Roux-en-Y gastric bypass and n = 2 to laparoscopic
sleeve gastrectomy).
All the following experiments for gene expression
and DNA methylation were conducted in a blind way
to reduce or eliminate experimental biases. NM and GC
participated in the recruitment of IGR participants,
sample collection and labelling. SA participated in the
recruitment, sample collection and labelling of bariatric
surgery patients. HAF and KS conducted all the mole-
cular biology experiments.
2.2. Gene expression analysis
All IGR participants and controls had 5 ml of peripheral
blood (PAXGene tubes) and both IGR, controls and bar-
iatric surgery patients had a punch of subcutaneous fat
tissue collected for subsequent DNA and RNA extraction.
Genomic DNA and RNA were extracted using AllPrep
DNA/RNA Mini Kit (Qiagen, Valencia, CA). Gene
expression analyses were conducted for 18 genes in fat
tissue (PPARG, GIPR, IGF2BP2, FTO, CAV1, IGF1 R,
INSR, IGFBP4, WFS1, IGF1, LPL, IGFBP2, IGF2,
IGFBP6, LEP, LDLR, IGFR2, HHEX), known to be impli-
cated in the modulation of weight change and interven-
tions as diet and exercise, impaired glucose regulation and
type 2 diabetes. Total RNA was extracted using the All
prepDNA/RNAmini kit (Qiagen, Valencia). The viability
and quantity of the RNAwere determined by NanoDrop®
ND-1000 spectrophotometer (Nanodrop, Wilmington,
DE). High-Capacity cDNA Reverse Transcription Kit
(Life Technologies, Foster City, CA) was used to synthe-
size cDNA by using approximately 400 ng of each RNA
sample, and 100 ng was then diluted in H2O.
Relative gene expression was determined using a
LightCycler 480 machine (Roche) running LightCycler
480 SW 1.5.0 SP3 software. The assays used in this study
were Roche RealTime ready single assays (PPARG, GIPR,
IGF2BP2, FTO, CAV1, IGF1 R, INSR, IGFBP4, WFS1,
IGF1, LPL, IGFBP2, IGF2, IGFBP6, LEP, LDLR, IGFR2,
HHEX) relative to two housekeeping genes (ACTB and
RN18S1). All genes were assayed in triplicate and 50 ng of
total cDNAwas used per reaction for all. The PCR protocol
was as follows: Pre-incubation – 1 cycle at 95ºC for 10 min,
Amplification – 50 cycles at 95ºC for 10 s, 60ºC for 30 s and
72ºC for 1 s, cooling– 1 cycle at 40ºC for 30 s. From those 18
genes analysed, we found significant alteration only in
CAV1 in fat tissue, so we also proceed to analyse the
expression in buffy coat following the same protocol.
Lymphoprep™ (Axis-Shield PoC AS, Oslo, Norway) was
used to obtain the mononuclear cells. The blood samples
were diluted 1:1 with physiological saline before being
applied to the gradient. The tubes containing
Lymphoprep™ and blood diluted in saline were centrifuged
at 800× g for 10 min at room temperature (15–25°C) with
the brake off. The concentrated leukocyte band (buffy coat)
was removed using a Pasteur pipette and used later to
extract DNA and RNA.
We quantified the gene expression using the
Comparative threshold (Ct) method (ΔΔCt method)
[18,19], and the amount of target gene was normalized
to ACTB as housekeeping gene (as it was stable across all
samples) and determined by 2−ΔΔCt, as previously
described [20,21], with relative expression levels reported
as fold change. Ct values higher than the cut-off of 35
were not considered as a reliable expression value, accord-
ing to the manufacturer’s recommendations, and there-
fore were excluded from the statistical analysis.
2.3. DNA bisulphite conversion and
pyrosequencing
The DNA of all IGR patients was bisulphite-treated to
convert unmethylated cytosine residues to uracil, we
performed this step using the EpiTec Fast DNA
Bisulphite Kit (Qiagen) with 99% mean conversion.
As we only found differences related to the lifestyle
intervention in gene expression for CAV1, DNA
sequences for CAV1 gene were identified in the 5ʹ
region that contains important transcription factor
(TF)-binding site sequences (using ALLGEN-PROMO
website: http://alggen.lsi.upc.es/cgi-bin/promo_v3/
promo/promoinit.cgi?dirDB=TF_8.3), and a pyrose-
quencing method was developed for determination of
methylation at 12 CpG sites within those sequences
following bisulphite reaction. The CpGs chosen to ana-
lyse are identified in Figure 1.
A measure of global methylation LINE-1 was deter-
mined using the set of primers PyroMark Q24 CpG
LINE-1 Catalogue no. 970012 (Qiagen, UK).
PCR reactions were carried out with 20 ng bisul-
phite-converted DNA using the PyroMark PCR kit in a
final volume of 12 µl containing 6 µl 1x PyroMark PCR
Master Mix, 1.25 µl 1x CoralLoad Concentrate, 0.5 µl of
each primer in a final concentration of 0.05 µM, 4 µl
RNase-free water. Amplification conditions were done
as follows: 95°C for 15 min, 45 cycles of 94°C for 30 s,
56°C for 30 s and 72°C for 30 s, finally, 72°C for
10 min. The methylation levels in the promoter
sequence of CAV1 were determined with a PyroMark
Q48 pyrosequencer (Qiagen UK) using 10 µl of PCR
product and a sequencing primer. Pyrosequence setup
and data reading were conducted by PyroMark Q48
2.4.2 software. We carried out our PCR and pyrose-
quencing experiments in duplicate; any inconsistencies
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between samples were resolved following further repe-
tition. The set of primers designed to analyse CAV1
promoter gene is described in Table 1.
2.4. Statistical analysis
We have done comparisons between patients pre-
(baseline) and post-intervention using paired T-test.
Statistical analysis was performed using the ‘Statistical
Package for Social Sciences’ (SPSS) version 22.0 (IBM
Corp: Armonk, NY: USA). We used p-value adjusted
for multiple comparisons (p ≤ 0.025). Age and sex were
used as covariates.
We also investigated possible correlations between
gene expression/DNA methylation and body measure-
ments as BMI, hip/waist ratio and weight, and between
gene expression and DNA methylation using partial
correlation (Pearson’s), p ≤ 0.05 were considered sig-
nificant and r coefficient interpreted according to
Mukaka (2012) and Schober et al. (2018) [22,23].
3. Results
The anthropometric measurements and demographic
data taken of the IGR patients before and after the
intervention were published in our previous study [7].
This clinical trial ended in 2018 due to adjustments in
the Care Call programme. Data regarding patients sub-
mitted to bariatric surgery are shown in Table 2.
3.1. Gene expression
Amongst all the genes analysed, only CAV1 showed
differences related to the lifestyle intervention
(Table 3).
The results related to gene expression in IGR indi-
viduals of CAV1 in both fat tissue and buffy coat blood
cells are shown in Figure 3. We found that the lifestyle
intervention (6 months) inhibited the expression of
CAV1 in fat tissue (t = 2.26, p = 0.025, n = 20)
(Figure 2(a)) while its expression was increased in
buffy coat blood cells (t = −2.76, p = 0.015, n = 20)
(Figure 2(b)).
Regarding those patients submitted to bariatric sur-
gery, we did not find significant differences in CAV1
expression before and after surgery (t = – 0.744;
p = 0.473, n = 12) (Figure2(c)). Considering patients
with T2DM history, we found a discreet increase of
CAV1 expression after the surgery, however not achiev-
ing statistical significance (t = – 2.28, p = 0.084, n = 5)
(Figure 2(d)).
Additionally, the general linear model analysis
showed gender differences in gene expression for
CAV1 in both fat tissue and buffy coat after the lifestyle
Figure 1. Promoter region of Caveolin-1 (CAV1: Chromosome 7, NC_000007.14 (116524785.116561185)) showing the CpGs chosen
to be analysed (numbered 1 to 12 and underlined) and the location of each assay (Assay 1 and 2, red boxes) developed to
pyrosequencing those CpG targets. Results were calculated by Paired T-test and are shown as average ± SE. * p ≤ 0.025.
Table 1. Set of primers used for PCR (forward and biotinylated reverse) reactions and pyrose-
quencing (sequencing) of CAV1 promoter.
Primers (5ʹ–3ʹ) Assay 1 Assay 2
Forward GGTTAGTATGTTTGGGGGTAAAT TGAGATGGTTTAAGAATTTTGGAAAGTGTA
Reverse [BIO] ACATAAAACATTCCTAACTTCTCTT CCTAAAAAACCCCTAAACTAAAAAAACAC
Sequencing GTAGATTAGGAGGTAGGT TTAAGAATTTTGGAAAGTGTAA
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intervention (F = 18.6, p = 0.002 and F = 9.96,
p = 0.012, respectively) with a similar pattern seen at
baseline; women showed higher levels of CAV1 than
men in both cases (t = 5.04, p = 0.0001 in fat tissue and
t = 2.46, p = 0.034 in buffy coat, n = 10) (Figure 3).
3.2. DNA methylation
As we found gene expression changes in CAV1 induced
by the lifestyle intervention in IGR individuals, we
investigated the DNA methylation profile in these sam-
ples. We analysed 12 CpG sites within the promoter
region of CAV1 gene (Chromosome 7, NC_000007.14
(116524785.116561185)) and we found tissue-specific
changes in DNA methylation.
For fat tissue we found increased methylation in 2
CpG sites related to lifestyle intervention (CpG5: t = –
2.39, p = 0.025 and CpG9: t = – 2.66, p = 0.017), these
changes are shown in Figure 4. While for buffy coat
blood cells the overall effect was the opposite – the
majority of the CpGs showed decreased levels of
methylation after the intervention (CpG2: t = 2.58,
p = 0.021, CpG5: t = 3.72, p = 0.002, CpG6: t = 5.53,
p = 0.0001, CpG7: t = 3.38, p = 0.004) (Figure 5). LINE-
1 methylation analysis showed differences only in buffy
coat blood cells after the intervention (t = 3.46,
p = 0.003) (Figure 6).
3.3. Correlations
In order to account for the global LINE-1 methylation
observed in buffy coat, all the correlations were ana-
lysed by partial correlation and controlling for LINE-1.
We tested Pearson’s correlations between those
CpGs we found altered due to the lifestyle intervention
and the anthropometric measurements for both tissues.
There were associations between gene expression and
methylation: i) a positive moderated correlation
between CAV1 gene expression in buffy coat and
CpG5 methylation in fat tissue (r = 0.617, p = 0.043)
(Figure 7), ii) a negative moderated correlation between
CAV1 gene expression in fat tissue and CpG6 methyla-
tion in buffy coat (r = – 0.606, p = 0.028) (Figure 8).
Furthermore, because we found a sex difference in
gene expression for both buffy coat and fat tissue, we
analysed the correlation by gender and found a negative
correlation only in women of CAV1 gene expression in
fat with CpG7 methylation in buffy coat (r = – 0.959,
p = 0.041) (Figure 9).
We also found a positive moderated correlation
between CAV1 expression and waist measurements in
patients after the bariatric surgery (r = 0.600, p = 0.039)
(Figure 10(a)) and this correlation is even stronger
when considering only patients with T2DM history
(r = 0.931, p = 0.021) (Figure 10(b)).
4. Discussion
In this study, we evaluated how a lifestyle intervention
followed by weight loss could influence the gene
Table 3. Panel of genes analysed by RT-qPCR in fat tissue of impaired glucose regulation (IGR) patients (n = 20) before and
6 months after the lifestyle intervention. The results are shown as average ± SE. * p ≤ 0.025.
Fold change mean ± SE p value
Gene (Before) (After) T value (paired T-test) (*p ≤ 0.025)
PPARG 2.76 ± 0.9 1.62 ± 0.3 1.132 0.273
GIPR 2.96 ± 1.2 3.10 ± 0.6 −0.124 0.903
IGF2BP2 3.30 ± 1.3 2.30 ± 0.5 0.683 0.504
FTO 3.20 ± 0.7 1.81 ± 0.3 1.969 0.065
CAV1 1.85 ± 0.2 1.04 ± 0.1 2.263 0.025*
IGF1 R 1.70 ± 0.5 1.65 ± 0.4 0.066 0.948
INSR 1.70 ± 0.3 1.78 ± 0.5 −0.246 0.809
IGFBP4 3.30 ± 1.0 2.89 ± 0.6 0.431 0.672
WFS 2.91 ± 0.8 2.21 ± 0.5 0.820 0.424
IGF-I 2.01 ± 0.5 1.95 ± 0.4 0.089 0.930
LPL 9.90 ± 3.2 7.50 ± 2.0 0.817 0.426
IGFBP-2 1.65 ± 0.4 1.22 ± 0.1 1.161 0.262
IGF-II 3.71 ± 1.4 3.18 ± 0.8 0.451 0.658
IGFBP-6 2.60 ± 1.0 2.26 ± 0.4 0.338 0.739
LEP 15.4 ± 5.2 14.6 ± 4.6 0.124 0.903
LDLR 2.43 ± 1.0 1.04 ± 0.2 1.458 0.163
IGFR-2 2.30 ± 0.6 1.97 ± 0.4 0.759 0.458
HHEX 2.34 ± 0.5 2.22 ± 0.6 0.267 0.793
Table 2. Anthropometric measurements and demographic data
of patients submitted to bariatric surgery (n = 12).
Before After (*p < 0.025)
Age (years ± SD) 53.5 ± 6.7
Sex (% male) 0.08
BMI (Average ± SEM) 49.2 ± 2.3 36.3* ± 2.1
(p < 0.001)
Waist (cm) 133.1 ± 1.9 108.9* ± 3.8
(p < 0.001)
T2DM history (%) 41
Weight (kg, average ± SEM) 130.5 ± 5.6 98.5*±5.8
(p < 0.0001)
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expression and DNA methylation profile in fat tissue
and buffy coat from patients with IGR and we com-
pared these results with patients submitted to bariatric
surgery.
Our main findings are that the lifestyle intervention
resulted in changes in gene expression and DNA
methylation of CAV1 in a tissue-specific way.
Additionally, we found correlations between gene
expression and DNA methylation, suggesting crosstalk
between tissues. Furthermore, we found a correlation
between CAV1 expression and waist measurements
after bariatric surgery, suggesting that CAV1 expression
follows the same direction of abdominal fat deposition.
In other words, when the waist circumference increases
the CAV1 expression in fat tissue increases, as well as
when the waist reduces, the CAV1 expression also
reduces.
Caveolin-1 (CAV1), the main structural and func-
tional protein of caveolae, is a key mediator of the
insulin transduction pathway directly interacting with
the beta-subunit of insulin receptor (IR) [24]. CAV1
plays an essential role for a proper insulin response in
mature adipocytes, since its depletion causes insulin
resistance and glucose transporter-4 (Glut-4) degrada-
tion [25,26]. The opposite direction of changes in
CAV1 expression in fat tissue and blood after the inter-
vention is reflecting the weight reduction, suggesting a
compensatory mechanism resulting in less signal in fat
tissue followed by increased expression in blood. The
maintenance of CAV1 levels is important for a proper
insulin response and lipid storage as demonstrated
before that CAV1 null mice presented altered lipid
deposition and improper storage of lipids outside of
the adipose tissue [27].
Figure 2. Gene expression of Caveolin-1 (CAV1) in fat tissue (a); buffy coat (b) from patients with impaired glucose regulation (IGR) at
baseline and after a lifestyle change (6 months post-intervention); (c) fat tissue from patients submitted to bariatric surgery at
baseline and 6 months post-surgery; (d) fat tissue from patients with T2DM history submitted to bariatric surgery at baseline and
6 months post-surgery. Results were calculated by Paired T-test and Bonferroni correction, and are shown as average ± SE. *
p ≤ 0.025.
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CAV1 has also been associated with immune
response and inflammation; it has been shown that
CAV1 expression in fat tissue of T2DM patients is
linked with low-grade inflammation [28,29] stimulating
the production of major pro-inflammatory cytokines,
such as TNF-α, IL-6, IL-1. On the other hand, reduced
expression of Caveolin-1 in monocytes was inversely
correlated with Toll-like receptor (TLR) 4 levels in
T2DM and neuropathy patients suggesting that low
CAV1 expression in white cells could aggravate the
TLR4-mediated inflammatory cascade [30]. Evidence
has suggested that CAV1 plays an important part in
suppressing inflammation. It was has been shown that
upregulation of Caveolin-1 in murine macrophages
dramatically inhibits TNF-α and IL-6 production [31].
The interaction between the methylation and gene
expression across tissues also suggests that the methyla-
tion changes may underlie the expression of CAV1 due
to external factors, in this case, the lifestyle interven-
tion. It was previously shown that DNA methylation of
the promoter can control the CAV1 expression during
adipocyte differentiation and this process was
Figure 3. Sex differences in Caveolin-1 (CAV1) gene expression in fat tissue and buffy coat of patients with impaired glucose
regulation (IGR) at baseline and after a lifestyle change (6 months post-intervention). Results were calculated by Paired T-test and
are shown as average ± SE. * p ≤ 0.025, ** p ≤ 0.01.
Figure 4. DNA methylation levels at 12 CpG sites within the promoter region of Caveolin-1 (CAV1) in fat tissue of patients with
impaired glucose regulation (IGR) at the baseline and after 6 months of lifestyle change. Results were calculated by Paired T-test and
are shown as average ± SE. * p ≤ 0.025.
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accompanied by activation of IR and glucose uptake
[32]. The activation of CAV1 in peripheral blood may
be crucial for the maintenance of the equilibrium in the
insulin-response efficiency and controlling immune
response.
We also found a gender association with CAV1
expression; women expressed more CAV1 than men
post-intervention. Even though we did not find studies
showing higher levels of CAV1 in adipose tissue in
women, previous evidence demonstrated a role for
CAV1 in regulating sex hormone signalling [33];
furthermore, it was demonstrated that CAV1 expres-
sion is stimulated by 17-b-oestradiol (E2) and reduced
by dihydrotestosterone (DHT) in both in vitro and in
vivo studies [34], showing these hormones have oppo-
site effects on body weight parameters.
The CpGs chosen in this study are important bind-
ing sites for transcription factors (TF) that regulate
gene expression. It is important to highlight that at
CpGs 5 and 6 (those we found correlated to gene
expression) there is a binding site for aryl hydrocarbon
receptor (AhR). AhR is a ligand-activated TF which has
Figure 5. DNA methylation levels at 12 CpG sites within the promoter region of Caveolin-1 (CAV1) in buffy coat of patients with
impaired glucose regulation (IGR) at the baseline and after 6 months of lifestyle change. Results were calculated by Paired T-test and
are shown as average ± SE. * p ≤ 0.025.
Figure 6. LINE-1 methylation in fat tissue and buffy coat of patients with impaired glucose regulation (IGR) at the baseline and after
6 months of lifestyle change. Results were calculated by Paired T-test and are shown as average ± SE. * p ≤ 0.025.
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been associated with an organism’s response to envir-
onmental contaminants and may perturb endocrine
function [35]; for example, AhR-dependent chemicals
(as dioxin) downregulate the expression of PPARγ in
3T3 cells during adipogenesis, resulting in the inhibi-
tion of adipocyte differentiation [36]. Thus, the differ-
ential methylation pattern seen in fat and blood may
participate in the regulation of adipocyte
differentiation.
At CpG7 there is a TF-binding site for CAAT/enhan-
cer-binding protein β (C/EBPβ) which is involved in the
coordination of gene expression in adipose [37] and
crucial to adipogenesis process [38]; additionally, its
function is enhanced by DNA methylation [39]. We
found that this binding site is hypomethylated in buffy
coat and correlated with increased CAV1 gene expression
in fat tissue in women, revealing the inhibition of C/
EBPβ activity by decreased methylation.
Reduced levels of global DNA methylation (LINE-1)
have been associated with genomic instability and sus-
ceptibility to chronic diseases [40] and frequently used
as a control of epigenetic changes. The lifestyle
Figure 7. Positive Pearson correlation between CpG5 of fat tissue and Caveolin-1 (CAV1) expression in buffy coat of patients with
impaired glucose regulation (IGR) after the lifestyle intervention. r = 0.617, p = 0.043.
Figure 8. Negative Pearson correlation between CpG6 of buffy coat and Caveolin-1 (CAV1) expression in fat tissue of patients with
impaired glucose regulation (IGR) after the lifestyle intervention. r = – 0.606, p = 0.028.
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intervention caused a reduction in LINE-1 methylation
in buffy coat blood cells accompanied by similar
changes in fat tissue however not achieving signifi-
cance. LINE-1 methylation has previously been asso-
ciated with dietary intake. Individuals presenting with
higher LINE-1 methylation had higher daily intakes of
calories [41]. Lifestyle and dietary intake changes may
have a role in the regulation of LINE-1 methylation in
blood cells. It is important to highlight that our CAV1
methylation findings are independent of LINE-1
changes, showing that the lifestyle intervention modu-
lated a specific effect of this gene.
Interestingly CAV1 expression changes were more
robust after the lifestyle intervention than after bariatric
surgery in our study. This evidence suggests that CAV1
gene expression can be better modulated by an
improvement in lifestyle, such as healthier food
consumption and exercises than due to a more invasive
procedure.
Our study has some limitations due to the number
of participants, even though we have strength in that
participants consented to donate blood and fat tissue
pre- and post-intervention, which permitted us to iden-
tify tissue-specific responses after diet and exercise in a
timescale.
This is the first evidence showing tissue-specific gene
expression and DNA methylation changes in the CAV1
promoter gene in patients with IGR, accompanied by
gender differences in CAV1 expression. Our findings
suggest a role for CAV1 in modulating adipocyte func-
tion as a consequence of diet and exercise. These results
may underlie the mechanisms related to the T2DM
prevention and provide insights into new therapeutic
targets for diabetes prevention.
Figure 9. Negative Pearson correlation between CpG7 of buffy coat and Caveolin-1 (CAV1) expression in fat tissue of women patients
with impaired glucose regulation (IGR) after the lifestyle intervention. r = – 0.959, p = 0.041.
Figure 10. (a) Positive correlation between Caveolin-1 (CAV1) gene expression and waist measurements in patients submitted to
bariatric surgery (6 months post-surgery) r = 0.600; p = 0.039. (b) Positive correlation between CAV1 gene expression and waist
measurements in patients with T2DM history submitted to bariatric surgery (6 months post-surgery), r = 0.931; p = 0.021.
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